Results 351 to 360 of about 342,150 (384)

Interpretation of HBV Serologies

Clinics in Liver Disease, 2021
Hepatitis B was discovered by researchers who were investigating jaundice associated with blood transfusions as well as parenterally administered medications. Through trial and error, the HBV was identified. There are specific tests that detect HBV infection, whether it is a previous exposure or active infection. The various HBV serologies are reviewed
Philippe J, Zamor, Ashley M, Lane
openaire   +2 more sources

Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stage of infection

Gut, 2018
Objective Chronic HBV infection affects more than 250 million people worldwide and remains a global healthcare problem in part because we lack curative treatment.
Ruben C. Hoogeveen, Maxwell Robidoux, T. Schwarz, Laura Heydmann, James A. Cheney, Daniel Kvistad, Jasneet Aneja, J. Melgaço, Carlos A S Fernandes, R. Chung, A. Boonstra, A. Kim, T. Baumert, J. Timm, L. Lewis-Ximenez, P. Tonnerre, G. Lauer   +16 more
semanticscholar   +1 more source

���������������� ������������ ������ ������ ������ �������������������� ��(HBV)

2005
The study of hepatitis B virus (HBV) kinetics during antiviral therapy contributes to understanding the mechanisms of infection, treatment antiviral effects and treatment failures. HBV DNA kinetics have been poorly characterized in HBeAg-negative chronic hepatitis B (CHB) patients.
openaire   +1 more source

Structure of the bile acid transporter and HBV receptor NTCP

Nature, 2022
Jinta Asami, K. Kimura, Yoko Fujita-Fujiharu, H. Ishida, Zhikuan Zhang, Y. Nomura, Kehong Liu, Tomoko Uemura, Yumi Sato, M. Ono, Masaki Yamamoto, Takeshi Noda, H. Shigematsu, D. Drew, S. Iwata, Toshiyuki Shimizu, N. Nomura, U. Ohto   +17 more
semanticscholar   +1 more source

Treatment options in HBV

Journal of Hepatology, 2006
The available evidence on interferon-alpha (IFN) treatment for chronic hepatitis B is sufficient to conclude that in patients with HBeAg positive chronic hepatitis, standard IFN therapy significantly improves clearance of HBeAg (number needed to treat [NNT] = 4), loss of HBV-DNA (NNT = 4) and clearance of HBsAg (NNT = 18).
CRAXI, Antonio, ANTONUCCI G, CAMMA', Calogero   +2 more
openaire   +3 more sources

A novel, small anti-HBV compound reduces HBsAg and HBV-DNA by destabilizing HBV-RNA

Journal of Gastroenterology
Currently, standard treatments for chronic hepatitis B such as nucleos(t)ide analogs (NAs), effectively reduce hepatitis B virus (HBV) loads but rarely result in a functional cure (defined as sustained HBsAg loss). We report the discovery of a novel, 4-pyridone compound, SAG-524, a potent and orally bioavailable small molecule inhibitor of HBV ...
Takehisa Watanabe, Sanae Hayashi, Yan Zhaoyu, Hiroki Inada, Katsuya Nagaoka, Masakuni Tateyama, Yasuhito Tanaka   +6 more
openaire   +2 more sources

HBV/HDV COINFECTION

The Lancet, 1987
F. Caredda, S. Antinori, C. Pastecchia, M. Moroni   +3 more
openaire   +3 more sources

Mechanisms of HBV-induced hepatocellular carcinoma.

Journal of Hepatology, 2016
M. Levrero, J. Zucman‐Rossi
semanticscholar   +1 more source

Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B

Nature Medicine, 2017
P. Fisicaro, Valeria Barili, B. Montanini, Greta Acerbi, M. Ferracin, F. Guerrieri, D. Salerno, C. Boni, M. Massari, M. C. Cavallo, G. Grossi, T. Giuberti, P. Lampertico, G. Missale, M. Levrero, M. Levrero, S. Ottonello, C. Ferrari   +17 more
semanticscholar   +1 more source

HBV vaccination reduces HBV-associated nephropathy

Inpharma Weekly, 2003
openaire   +1 more source